SynthesisJournal of cellular and molecular medicine2025
The Role of Radiotherapy After Full Course of Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.
Synthesis in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Role of Radiotherapy After Full Course of Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rituximab has improved response rates and overall survival in diffuse large B-cell lymphoma (DLBCL). Radiotherapy (RT) is an effective treatment modality for lymphomas. However, significant conceptual challenges, including the application in elderly patients, varying IPI scores and CR patients, remain regarding the current use of RT. We performed a systematic review comparing chemotherapy with RT to chemotherapy alone in patients with DLBCL. We estimated hazard ratios (HR) for OS, PFS and EFS using the proportional hazards model. Five articles involving 1364 patients met inclusion criteria. Patients undergoing consolidative RT had better OS (HR = 0.46, 95% CI 0.31-0.68), PFS (HR = 0.52, 95% CI 0.22-1.25) and EFS (HR = 0.42, 95% CI 0.20-0.90) compared to those who received no RT. But no benefit was shown in patients with achievement of CR. The protective effect of consolidation RT for patients with advanced IPI scores (HR = 0.46, 95% CI 0.31-0.68) and advanced stage (HR = 0.22, 95% CI 0.08-0.59) was shown. The consolidation RT showed a significantly longer PFS (HR = 0.50, 95% CI 0.26-0.94) but no significant benefit on OS in patients with bulky disease. There was also significantly better PFS in RT patients (HR = 0.67, 95% CI 0.49-0.92), but no significant benefit on OS in old age patients. RT act as an efficacious method for DLBCL following a full course of chemotherapy. However, no OS benefit was shown in patients with advanced IPI scores, bulky disease, CR and old age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.